It targets the glucagon receptor (GCGR) in the liver, thus contributing to ameliorating T2D.416 Vupanorsen is an N-acetyl galactosamine-conjugated ASO that selectively reduces production of angiopoietin-like 3 (ANGPTL3) in the liver by targeting its mRNA. This evidence concerns the gene GCGR and type 2 diabetes mellitus.